sotevtamab   Click here for help

GtoPdb Ligand ID: 11763

Synonyms: 16B5 [1] | AB-16B5 | AB-sCLU mAb | AB16B5
Compound class: Antibody
Comment: Sotevtamab (AB-16B5) is a humanized IgG2 antibody against secreted clusterin. It was developed by Alethia Biotherapeutics for anti-cancer potential. Peptide sequences of the heavy and light chains of the antibody are claimed in patent WO2011063523A1 [1], via which sotevtamab can be linked to the antibody designated as humanised 16B5. Sotevtamab is expected to inhibit clusterin-induced epithelial to mesenchymal transition, as a mechanism to both reduce tumour invasion and augment the response to standard of care chemotherapy.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Sotevtamab (AB-16B5) has progressed to clinical evaluation in advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02412462 Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy Phase 1 Interventional Alethia Biotherapeutics
NCT04364620 AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) Phase 2 Interventional Alethia Biotherapeutics